• FirefoxInstall the new Firefox »
  •  Dow Up1.49% Nasdaq Up1.15%

    Echo Therapeutics, Inc. (ECTE)

    2.37 Down 0.04(1.66%) 3:53PM EDT
    Add to Portfolio
    ProfileGet Profile for:
    Echo Therapeutics, Inc.
    99 Wood Avenue South
    Suite 302
    Iselin, NJ 08830-2734
    United States - Map
    Phone: 508-553-8850
    Website: http://www.echotx.com

    Index Membership:N/A
    Industry:Drug Manufacturers - Major
    Full Time Employees:28

    Business Summary 

    Echo Therapeutics, Inc. is engaged in the development of transdermal skin permeation and diagnostic medical devices. It is developing Symphony CGM system (Symphony), a needle-free wireless continuous glucose monitoring system for use in hospital critical care units; and Symphony SkinPrep system, a component of its Symphony for enhanced skin permeation that enables extraction of analytes, such as glucose. The company is also engaged in the development Durhalieve, an AzoneTS formulation of triamcinolone acetonide that has completed Phase III clinical trials for the treatment of corticosteroid-responsive dermatoses. It has a licensing agreement with Ferndale Pharma Group, Inc. to develop, market, sell, and distribute Prelude SkinPrep system for skin preparation prior to the application of topical anesthetics prior to a range of needle-based medical procedures in North America, the United Kingdom, South America, Australia, New Zealand, Switzerland, and other portions of the European Community; a license agreement with Handok Pharmaceuticals Co., Ltd. to develop, use, market, import, and sell Symphony for continuous glucose monitoring for use by medical facilities and/or individual consumers in South Korea; and a license, development, and commercialization agreement with Medical Technologies Innovation Asia, Ltd. The company was founded in 1989 and is headquartered in Iselin, New Jersey.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Echo Therapeutics, Inc.

    Key Executives 
    Mr. Scott W. Hollander ,
    Chief Exec. Officer, Pres and Director
    Mr. Charles T. Bernhardt CPA, M.B.A., 54
    Interim Chief Financial Officer
    Mr. Alan W. Schoenbart CPA, 56
    Chief Financial Officer
    Mr. Thomas H. Bishop , 58
    VP of Operations and Product Devel.
    Ms. Christine H. Olimpio ,
    Director of Investor Relations & Corp. Communications
    Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders